However, anti-PD-1 monotherapy has failed to show efficacy in randomized phase III clinical trials for either recurrent (NCT02017717) or newly diagnosed GBM (NCT02617589) [200, 202, 203]. This evidence concerns the gene PDCD1 and glioblastoma.